Page last updated: 2024-09-04

cositecan and Benign Neoplasms

cositecan has been researched along with Benign Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailly, C; Lansiaux, A1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH1

Other Studies

2 other study(ies) available for cositecan and Benign Neoplasms

ArticleYear
[A symphony for the camptothecins].
    Bulletin du cancer, 2003, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan

2003
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    International journal of cancer, 2000, Oct-15, Volume: 88, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000